Align Technology (NASDAQ:ALGN) been upgraded to outperform from market perform by Leerink Partners. Calling Align ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

Leerink downgraded Accolade (ACCD) to Market Perform from Outperform with a price target of $7.03, down from $9.50, after the company agreed to ...

Leerink Partnrs upgraded shares of Align Technology (NASDAQ:ALGN – Free Report) from a hold rating to a strong-buy rating in a research note released on Monday morning,Zacks.com reports. ALGN has been ...

Leerink upgraded Align Technology (ALGN) to Outperform from Market Perform with a price target of $280, up from $235. For what remains a clear ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Look for renewed investment driven by lower interest rates in the new year, and a continued focus on late-stage assets, ...

CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...